Novel Gout Drug Aces Mid-Stage Tests
SAN DIEGO — An investigational once-daily oral agent that inhibits urate transporter-1 (URAT1) as a means of forcing uric acid excretion showed good efficacy and safety in a pair of phase II trials reported here. In one of these studies, the new product, called AR882 for the time being, reduced serum urate by 40% to […]